Wegovy Dose Pens: How the Dosing Schedule Actually Works

How are the Wegovy dose pens different from each other?

Each pen in the Wegovy range is pre-filled and colour-coded to its specific strength, with a covered needle that locks after use. You do not draw up a dose or make any adjustment, what's in the pen is what you inject, once a week, under the skin of your abdomen, thigh, or upper arm. Rotate the injection site each week to reduce local reactions.

The standard UK maintenance pathway runs: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, and if you want to see how each of those Wegovy pens and their doses sit alongside one another, that page lays it out clearly. The NHS patient information page for semaglutide on nhs.uk describes this schedule clearly and is worth bookmarking alongside the Patient Information Leaflet that arrives with your pens. Storage is refrigerated (2–8°C); the exact window for keeping a pen at room temperature is stated in that leaflet, so follow it rather than any general advice online.

The 7.2 mg pen, approved in April 2026, is a single pre-set weekly injection with an auto-dosing mechanism, no dial, no guesswork. It is licensed for adults with a BMI of 30 or above only, and the titration still starts at 0.25 mg rather than jumping straight to the higher dose. If you are curious about where the 7.2 mg fits alongside earlier strengths, the full breakdown of all Wegovy doses covers the detail.

What does each dose pen actually do to your appetite?

Semaglutide mimics a hormone called GLP-1 that is released naturally after eating. It signals to the brain that you are full, slows the speed at which your stomach empties, and reduces overall calorie intake over time. The lower doses (0.25 mg and 0.5 mg) are primarily there to let your body acclimatise. Gastrointestinal side effects (nausea, loose stools, constipation, burping) are most common around dose changes and typically settle within a week or two for most people.

The therapeutic effect on weight builds as the dose increases. In the STEP 1 trial, published in the New England Journal of Medicine, participants taking 2.4 mg semaglutide weekly for 68 weeks lost around 15% of body weight on average alongside lifestyle changes. Trial participants who moved to the 7.2 mg dose in subsequent studies saw results approaching 20%, narrowing the gap with tirzepatide. Those numbers come from controlled trials; real-world outcomes vary, and a prescriber will help you understand what is realistic for your starting point. The Wegovy treatment overview has more on the evidence behind those figures.

One thing our prescribers hear regularly: people assume the starter pen is not working. It is, it is just working on tolerance first. Give each level its time before drawing conclusions.

Does moving up a dose pen require a new prescription?

Yes. Every dose change is a new clinical decision, not an automatic step. A prescriber reviews your progress (weight loss to date, side effects, any new health information) before approving the next pen, and our page on Wegovy pens dosage explains how that decision-making process works in practice. At nume, that review happens before each repeat order is dispensed; a named clinician reads your answers, not software. If a dose increase is appropriate, the prescription is issued the same day if the assessment supports it, and your pen is dispatched for free next-working-day delivery via DPD. The tracking notification arrives on your phone before the plain, unbranded box does.

Dose reductions are also a legitimate clinical choice, not a failure. If 2.4 mg causes persistent side effects, staying at 1.7 mg is a reasonable long-term plan for some people. What matters is sustainable treatment, not hitting the top of the ladder. For questions about how a specific dose is chosen for your situation, the guide to how Wegovy dosing is decided goes into more depth, and our FAQs cover the most common queries about repeats and reviews.

Is there a 'right' dose pen that delivers the best results?

There is no universally optimal dose; there is only the highest dose that a given person tolerates well and that their prescriber considers appropriate. Some people reach 2.4 mg without difficulty and see strong weight loss; others find 1.7 mg the ceiling and still lose clinically meaningful amounts of weight. The idea that everyone should push to the maximum is a misconception worth setting aside early.

The 7.2 mg pen adds a new option at the top of the range, but it is not automatically superior for every patient, eligibility criteria differ (BMI of 30 or above, not the standard 27+ threshold for lower doses), and the evidence base is newer. If you want a nuanced look at whether there is a sweet spot in the schedule, the page on whether Wegovy pens have a golden dose addresses that question directly.

What a prescriber weighs up is your overall picture: starting weight, how your body has responded to previous steps, any side effects, and whether you are losing at a clinically meaningful rate. The MHRA's approval of each dose is based on a carefully assessed risk-benefit profile for the licensed population, not a blanket endorsement that more is always more. You can read NICE's appraisal of semaglutide for weight management at NICE TA875 for the official UK recommendation framework.

If you are weighing up your options or wondering whether Wegovy treatment is right for you, start a free consultation with our prescribers, who can talk through the whole schedule with your specific circumstances in mind.